newsfilter
← Latest News
Business Wire·

Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026

  • Viridian Therapeutics, Inc. will host a conference call & webcast on Monday, November 9, 2026, at 8:00 a.m. ET to present VRDN-008 phase 1 trial data in healthy volunteers & discuss FcRn portfolio development plans.
  • Domestic dial-in number is +1 833-461-5787, international dial-in number is +1 585-542-9983, & conference ID is 798750309.
  • Live webcast & archived recording will be accessible under "Events & Presentations" in the Investors section of viridiantherapeutics.com.
  • The company has an FDA-approved full IGF-1R antagonist, LumvoaTM, for thyroid eye disease (TED) & is advancing investigational subcutaneous therapy elegrobart for TED.
  • Viridian Therapeutics is based in Waltham, Massachusetts, & focuses on discovering & developing medicines for autoimmune & rare diseases.